The Effects of GLP-1 Receptor Agonists on Body Composition in Patients With Type 2 Diabetes, Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials
In the last decade, several cardiovascular outcomes trials (CVOT) have been conducted in order to explore cardiovascular benefit of GLP-1 receptor agonists
Patients who rely solely on the medication without changing habits are nearly guaranteed to regain when they stop
However, interfering with miR-100-5p expression in exosomes significantly attenuated this therapeutic effect
Disclosures: Jeff Li: Nothing to Disclose, Katrina Jorritsma: Nothing to Disclose, Natasha Campeau: Nothing to Disclose, Agatha Vranjkovic: Nothing to Disclose, Jood Madani: Nothing to Disclose, Torki Alothaimeen: Nothing to Disclose, Angela Cheung: Nothing to Disclose, Michele Ardolino: Nothing to Disclose, Angela Crawley: Nothing to Disclose 982 MONOCYTE TRANSCRIPTOMIC LANDSCAPE AND INTER-ORGAN CROSSTALK BETWEEN THE LIVER, BRAIN AND BONE MARROW IN A MODEL OF ALCOHOL MISUSE IN AGING Marti Ortega-Ribera 1 Radhika Joshi 1 Sergi Guix-Muntet 2 Veronika Brezani 1 Prashanth Thevkar Nagesh 3 Viliam Brezani 1 Arman Patel 1 Mrigya Babuta 1 Yuan Zhuang 1 Jordi Gracia-Sancho 4 Gyongyi Szabo 5 , 1 BIDMC - Harvard Medical School, 2 IDIBAPS, 3 Beth Israel Medical Center, 4 IDIBAPS - Hospital Clnic Barcelona, 5 Beth Israel Deaconess Medical Center Background: The globally increasing aging population exhibits high vulnerability to infections due to inflammaging (basal pro-inflammatory state) and decreased efficiency to fight pathogens
Approach GLP-1 probiotic claims with appropriate skepticism, prioritizing evidence-based interventions for metabolic health management
